New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2013
10:02 EDTMM, ZFC, NSLP, HIIQ, CMRE, KBIO, SUPN, NFLX, A, EDAP, SRPT, ISRG, ANTH, AYI, EOPN, CACC, MITT, DYAX, AEGROn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AG Mortgage (MITT) initiated with a Neutral at Credit Suisse... Acuity Brands (AYI) initiated with a Buy at UBS... Aegerion (AEGR) initiated with a Buy at BofA/Merrill... Anthera Pharmaceuticals (ANTH) initiated with a Buy at Jefferies... Credit Acceptance (CACC) initiated with an Outperform at JMP Securities... Diana Shipping (DSX) initiated with a Neutral at JPMorgan... Dyax (DYAX) initiated with a Buy at Jefferies... E2open (EOPN) initiated with a Buy at Benchmark Co.... Health Insurance Innovations (HIIQ) initiated with an Outperform at Credit Suisse... Intuitive Surgical (ISRG) initiated with an Underperform at Northland Securities... Netflix (NFLX) initiated with an Outperform at RBC Capital... New Source Energy (NSLP) initiated with an Outperform at RW Baird... Sarepta (SRPT) initiated with an Outperform at Leerink... Supernus Pharmaceuticals (SUPN) initiated with a Buy at Jefferies... ZAIS Financial (ZFC) initiated with a Buy at Citigroup, initiated with an Outperform at Credit Suisse and initiated with an Overweight at Barclays... EDAP TMS (EDAP) initiated with an Outperform at Northland Securities... Health Insurance Innovations (HIIQ) initiated with a Strong Buy at Raymond James... KaloBios (KBIO) initiated with a Buy at Needham... Millennial Media (MM) initiated with a Hold at Needham... ZAIS Financial (ZFC) initiated with a Perform at Oppenheimer... Agilent (A) initiated with an Outperform at Credit Suisse... Costamare (CMRE) initiated with an Overweight at JPMorgan.
News For MITT;AYI;AEGR;CACC;ANTH;DYAX;EOPN;HIIQ;ISRG;NFLX;NSLP;SRPT;SUPN;ZFC;EDAP;KBIO;MM;A;CMRE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 >>
August 20, 2015
09:17 EDTNFLXDisney hit with another downgrade on TV concerns
Subscribe for More Information
09:08 EDTAYIEnergy Focus price target raised to $23 from $16 at Roth Capital
Subscribe for More Information
August 19, 2015
16:00 EDTNFLXOptions Update; August 19, 2015
Subscribe for More Information
10:57 EDTNFLXT-Mobile promotion gives Netflix analyst greater confidence
UBS raised its price target on Netflix (NFLX) to $143 from $116, saying that its confidence in the company's outlook has improved following a promotion undertaken by T-Mobile (TMUS). WHAT'S NEW: T-Mobile recently began offering one free year of Netflix to consumers who switch to its wireless service, UBS analyst Doug Mitchelson wrote in a note to investors today. Mitchelson said that the promotion increases his confidence in the outlook for Netflix's U.S. business. Moreover, he believes that Netflix could "become a standard promotional tool" for wired and wireless broadband providers going forward. Although Netflix's stock "looks very expensive" in the near-term, the company's long-term opportunity is "extraordinary," given the potential size of the global streaming market, the analyst stated. Mitchelson's "upside case" for Netflix shares is $199 while his "downside case" is $55. The downside case assumes Hollywood starts restricting content licensing to streaming services like Netflix in attempt to slow their growth. He raised his price target on the name to $143 from $116 and kept a Buy rating on the shares. WHAT'S NOTABLE: On August 10, research firm Stifel raised its price target on Netflix to $143 from $128, saying that the company's U.S. subscriber base can reach 80M by 2024, above the midpoint of its guidance. PRICE ACTION: In mid-morning trading, Netflix fell 1% to $122.
09:33 EDTNFLXActive equity options trading on open
Active equity options trading on open: AAPL BAC FB BA TWTR NFLX WMT BABA
09:17 EDTSRPT'Female Viagra' approval seen as positive for Sarepta, BioMarin
The FDA's approval of the world's first drug designed to boost a woman's sexual desire is seen as boding well for companies awaiting critical decisions by the agency. FEMALE VIAGRA: The Food and Drug Administration yesterday approved flibanserin to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women. The drug, which will be sold under the name "Addyi" and is commonly referred to as the "female Viagra," is the first FDA-approved treatment for sexual desire disorders in men or women, the agency prominently stated in its press release. HSDD is characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance, the FDA explained. Addyi was approved with a risk evaluation and mitigation strategy as well as a Boxed Warning given the risk of severe hypotension and syncope in patients who drink alcohol during treatment. The drug is made by privately held Sprout Pharmaceuticals. ANALYST REACTION: Addyi's approval is "another sign of flexibility" by the FDA, especially for first-in-class therapies, Roth Capital analyst Debjit Chattopadhyay writes this morning in a note to investors. This bodes well for the approval of eteplirsen, drisapersen and Translarna, the analyst contends. Eteplirsen, designed by Sarepta Therapeutics (SRPT), and drisapersen, designed by BioMarin (BMRN), are experimental drugs being developed to treat Duchenne muscular dystrophy. Translarna, designed by PTC Therapeutics (PTCT), is already being sold in Europe as a treatment for DMD and is awaiting approval from the FDA. Duchenne muscular dystrophy is a form of muscular dystrophy affecting around 1 in 3,600 boys, which results in muscle degeneration and premature death. SAVING LIVES: While female sexual dysfunction is a clinical problem, eteplirsen is designed to save lives, Chattopadhyay points out. He has a Buy rating on Sarepta and noted his price target of $45 assumes accelerated approval for eteplirsen in the first quarter of 2016. Shares of the Massachusetts-based biopharmaceutical company closed yesterday at $35.69.
08:29 EDTSRPTFlibanserin approval bodes well for Sarepta, others, says Roth Capital
Subscribe for More Information
06:01 EDTNFLXNetflix price target raised to $143 from $116 at UBS
UBS analyst Doug Mitchelson raised his price target for Netflix (NFLX) shares to $143 after increasing his longer term revenue assumptions. The streaming service closed yesterday down $1.31 to $124.05. Mitchelson upped his 2020-2026 revenue estimates to reflect his belief that Netflix will successfully monetize its streaming platform beyond just monthly subscription fees, such as bundling and promoting third party services. He has increased confidence in the company's U.S. growth outlook after T-Mobile (TMUS) just launched a promotion for its wireless service that included one free year of Netflix. As competition among broadband providers intensifies, Netflix's inexpensive monthly streaming service could become one of the standard promotional tools, Mitchelson tells investors in a research note. The analyst's "upside case" for Netflix shares is $199 while his "downside case" is $55. The downside case assumes Hollywood starts restricting content licensing to streaming services like Netflix in attempt to slow their growth. Mitchelson keeps a Buy rating on Netflix.
August 18, 2015
16:00 EDTNFLXOptions Update; August 18, 2015
Subscribe for More Information
11:14 EDTNFLXStocks with call strike movement; NFLX VALE
Subscribe for More Information
09:39 EDTNFLXActive equity options trading on open
Subscribe for More Information
August 17, 2015
17:48 EDTAAgilent says confident in delivering on margin expansion goals
On the company Q3 earnings conference call, Agilent said that it is confident in delivering on margin expansion goals. The company noted that it is committed to a 22% operating margin by 2017 and will continue its buybacks in Q4. The company sees a number of areas of strength including Pharma, Life Science, Research and Diagnostics. The company is seeing double-digit growth in Pharma and has no reason to believe it will slow down. Agilent sees "a lot " of reasons to be positive on outlook.
16:21 EDTAAgilent says some U.S. and state government large deals delayed into Q4
Agilent said in a slides presentation that some US and state government large deals delayed into Q4. Customers in industrial markets continue cautious stance in light of macro-economic conditions.
16:09 EDTAAgilent narrows FY15 EPS view to $1.68-$1.72 from $1.67- $1.73
Subscribe for More Information
16:07 EDTAAgilent sees Q4 EPS 45c-49c, consensus 50c
Sees Q4 revenue $1.03B-$1.05B, consensus $1.06B.
16:06 EDTAAgilent reports Q3 EPS 44c, consensus 41c
Subscribe for More Information
14:48 EDTANotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Agilent (A), consensus 41c... Urban Outfitters (URBN), consensus 49c... MasTec (MTZ), consensus 15c... Fabrinet (FN), consensus 39c.
12:23 EDTNFLXStocks with call strike movement; Netflix J.C. Penney
Netflix (NFLX) January 150 call option implied volatility increased 2% to 48, J.C. Penney (JCP) January 10 call option implied volatility increased 1% to 40 according to IVolatility.
09:38 EDTNFLXActive equity options trading on open
Active equity options trading on open: AAPL FB BAC MU NFLX TWTR HUN TSLA BABA MSFT
06:22 EDTSRPTPiper's Tenthoff sees select biotech names outperforming in second half
Piper Jaffray analyst Edward Tenthoff expects drug launches, clinical data read-outs and potential partnerships to drive outperformance for select biotech names in the second half of 2015. Despite some recent profit-taking, 2015 has been another strong year for biotech stocks, Tenthoff tells investors in a research note. Names with important second half of the year catalysts include Vertex (VRTX), Regeneron (REGN), Seattle Genetics (SGEN), Exelixis (EXEL), Sarepta (SRPT), Novavax (NVAX), Arrowhead (ARWR), Array BioPharma (ARRY), Alnylam (ALNY), Genocea (GNCA), CymaBay (CBAY), Idera Pharmaceuticals (IDRA), Vitae Pharmaceuticals (VTAE).
1 | 2 | 3 | 4 | 5 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use